- Sections
- A - Nécessités courantes de la vie
- A61K - Préparations à usage médical, dentaire ou pour la toilette
- A61K 31/137 - Arylalkylamines, p.ex. amphétamine, épinéphrine, salbutamol, éphédrine
Détention brevets de la classe A61K 31/137
Brevets de cette classe: 4390
Historique des publications depuis 10 ans
|
438
|
435
|
403
|
416
|
442
|
443
|
475
|
448
|
382
|
117
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Antecip Bioventures II LLC | 300 |
163 |
| Novartis AG | 11238 |
63 |
| The Regents of the University of California | 18943 |
44 |
| Zogenix International Limited | 77 |
43 |
| Grünenthal GmbH | 625 |
42 |
| The Procter & Gamble Company | 22178 |
38 |
| Nalpropion Pharmaceuticals LLC | 72 |
38 |
| Noven Pharmaceuticals, Inc. | 106 |
30 |
| Gruenenthal GmbH | 120 |
28 |
| Pharnext | 106 |
26 |
| Axsome Therapeutics, Inc. | 213 |
25 |
| Nevakar Injectables Inc. | 36 |
23 |
| Aquestive Therapeutics, Inc. | 160 |
21 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2737 |
20 |
| Radius Pharmaceuticals, Inc. | 63 |
20 |
| The Trustees of Columbia University in the City of New York | 3440 |
19 |
| Boehringer Ingelheim International GmbH | 4629 |
18 |
| Ironshore Pharmaceuticals & Development, Inc. | 33 |
18 |
| Nova Southeastern University | 86 |
18 |
| Tonix Pharma Holdings Limited | 44 |
17 |
| Autres propriétaires | 3676 |